Patents by Inventor Michael Kaleko

Michael Kaleko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbiome protection from oral antibiotics
    Patent number: 12274740
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: April 15, 2025
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20250000953
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Application
    Filed: June 17, 2024
    Publication date: January 2, 2025
    Inventors: Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
  • Beta-lactamase formulations and uses thereof
    Patent number: 12178917
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 31, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS
    Publication number: 20240269247
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
    Type: Application
    Filed: December 11, 2023
    Publication date: August 15, 2024
    Inventors: Michael KALEKO, Sheila CONNELLY
  • ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE
    Publication number: 20240252599
    Abstract: The present disclosure relates, inter alia, to therapeutic intestinal alkaline phosphatases for the treatment of celiac disease.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 1, 2024
    Inventor: Michael KALEKO
  • Alkaline phosphatase formulations
    Patent number: 12048735
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: July 30, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
  • METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS
    Publication number: 20240197842
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: February 29, 2024
    Publication date: June 20, 2024
    Inventors: Michael KALEKO, Sheila CONNELLY, Vincent John WACHER
  • -based production of beta-lactamase
    Patent number: 11981899
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: May 14, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Steven Hubert
  • Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
    Patent number: 11944669
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: February 2, 2023
    Date of Patent: April 2, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Microbiome protection from oral antibiotics
    Patent number: 11883474
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: January 30, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS
    Publication number: 20230405099
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: February 2, 2023
    Publication date: December 21, 2023
    Inventors: Michael KALEKO, Sheila CONNELLY, Vincent John WACHER
  • METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE
    Publication number: 20230398194
    Abstract: The present invention provides, in part, therapeutic beta-lactamases that can, inter alia, mitigate antibiotic resistance.
    Type: Application
    Filed: May 25, 2023
    Publication date: December 14, 2023
    Inventors: Sheila CONNELLY, Michael KALEKO
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20230313166
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: February 7, 2023
    Publication date: October 5, 2023
    Inventors: Michael KALEKO, Sheila CONNELLY
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS
    Publication number: 20230310558
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Application
    Filed: April 14, 2023
    Publication date: October 5, 2023
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20230277466
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 7, 2023
    Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
  • E. COLI-BASED PRODUCTION OF BETA-LACTAMASE
    Publication number: 20230279409
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Application
    Filed: December 1, 2022
    Publication date: September 7, 2023
    Inventors: Andrew BRISTOL, Michael KALEKO, Steven HUBERT
  • MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS
    Publication number: 20230270830
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
    Type: Application
    Filed: October 26, 2022
    Publication date: August 31, 2023
    Inventors: Michael KALEKO, Sheila CONNELLY
  • Alkaline phosphatase agents for treatment of radiation disorders
    Patent number: 11654184
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 23, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Christian Furlan Freguia, Sheila Connelly
  • Intestinal alkaline phosphatase formulations
    Patent number: 11638699
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 2, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Ray Stapleton, Michael Kaleko, Christian Furlan Freguia, Steven Hubert, Cristina Freire, James Gubbins
  • Beta-lactamases with improved properties for therapy
    Patent number: 11608494
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: March 21, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly